EventsViruses 2026 – New Horizons in Virology
Published
This submission belongs to the session S5. Virus-Host Interactions of the event Viruses 2026 – New Horizons in Virology
Published date
09 Mar, 2026
Academic Editor
author-avatarEric Freed
Citation
Alexandros Belavilas-Trovas, Maria-Carla Saleh, Valerie Dorey, Annabelle Henrion-Lacritick, Hervé Blanc, Lionel Frangeul, Why Don't Mosquitoes Get Sick from Chikungunya Virus? Decoding Disease Tolerance Mechanisms in Aedes Mosquitoes, in Proceedings of Viruses 2026 – New Horizons in Virology, Barcelona, 11 March–13 March 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Why Don't Mosquitoes Get Sick from Chikungunya Virus? Decoding Disease Tolerance Mechanisms in Aedes Mosquitoes

Valerie Dorey 1
Annabelle Henrion-Lacritick 1
Hervé Blanc 1
1. Viruses & RNA Interference Unit, Department of Virology, Institut Pasteur, 75015, Paris, France, France
Abstract

The Chikungunya virus (CHIKV) is a positive-sense RNA alphavirus that circulates in nature by alternating replication between mammalian hosts and mosquito vectors, primarily Aedes aegypti and Aedes albopictus. Remarkably, while CHIKV infection causes significant disease in mammals, mosquitoes remain asymptomatic, reflecting the presence of powerful disease tolerance mechanisms within the vector. Previous studies have revealed that a key mechanism underlying this tolerance is the synthesis of viral DNA (vDNA) using the CHIKV RNA genome as a template. This conversion is mediated by endogenous retrotransposon-encoded reverse transcriptases (RTs) within the mosquito. Pharmacological inhibition of this process using classical reverse transcriptase inhibitors such as zidovudine (AZT) abrogates vDNA synthesis and impairs disease tolerance, leading to increased viral susceptibility. However, the molecular pathways governing vDNA biogenesis, as well as the distinct impacts of different classes of reverse transcriptase inhibitors in mosquitoes, remain poorly characterized.

To address these gaps, we investigated the mechanisms of vDNA synthesis both in vivo and in vitro. We mapped the reverse-transcribed regions of the CHIKV genome and characterized the kinetics of vDNA synthesis following infection. In parallel, we evaluated the comparative efficacy of five RT inhibitors—AZT, d4T, 3TC, nevirapine, and tenofovir—representing nucleoside analogs, nucleotide analogs, and allosteric inhibitors, in blocking vDNA synthesis in both mosquitoes and mosquito-derived cells. For each compound, we assessed cellular toxicity, viral loads, cell viability, and cytopathic effects, alongside quantification of vDNA inhibition. Finally, we performed transcriptomic analysis to dissect the broader impact of RT inhibition on mosquito antiviral immune mechanisms, cellular metabolism, and stress responses during CHIKV infection.

Our findings elucidate core molecular features of vDNA synthesis and demonstrate distinct inhibitor effects, advancing understanding of mosquito tolerance to viral disease and offering potential avenues for vector-targeted control strategies.

Keywords
Chikungunya
Arboviruses
Disease tolerance
Mosquitoes
Reverse Transcriptase Inhibitors
Viral DNA
SARS-CoV-2 Undergoes Receptor Switch during Endocytic Entry
Evaluation of the Antiviral Potential of Carica papaya Leaf Extracts Against Dengue Virus